scholarly journals Expression and Function of Toll-Like Receptor 10 (TLR10) in Diffuse Large B Cell Lymphoma, Acute Myeloid Leukemia, and Glioma

2020 ◽  
Vol 26 ◽  
Author(s):  
Le Ge ◽  
Lixia Xu ◽  
Shan Lu ◽  
Hua Yan
Keyword(s):  
Acute Myeloid Leukemia ◽  
B Cell ◽  
Myeloid Leukemia ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Toll Like Receptor ◽  
Large B Cell Lymphoma ◽  
And Function ◽  
Large B Cell ◽  
Acute Myeloid

scholarly journals Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia

2018 ◽  
Vol 57 (10) ◽  
pp. 1445-1453 ◽  
Author(s):  
Junichi Miyatake ◽  
Hiroaki Inoue ◽  
Kentarou Serizawa ◽  
Yasuyoshi Morita ◽  
JL Espinoza ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
B Cell ◽  
Mycosis Fungoides ◽  
Myeloid Leukemia ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Acute Myeloid

Secondary Diffuse Large B-cell Lymphoma After Chemotherapy for Acute Myeloid Leukemia

2014 ◽  
Vol 36 (7) ◽  
pp. e125-e128 ◽  
Author(s):  
Marnie R. Ririe ◽  
Scott R. Florell ◽  
Rodney R. Miles ◽  
Keith L. Duffy
Keyword(s):  
Acute Myeloid Leukemia ◽  
B Cell ◽  
Myeloid Leukemia ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Acute Myeloid

Roles of Polycomb gene EED in pathogenesis and prognosis of acute myeloid leukemia and diffuse large B cell lymphoma

2018 ◽  
Author(s):  
Wenhua Yu ◽  
Haiwei Du
Keyword(s):  
Acute Myeloid Leukemia ◽  
B Cell ◽  
Myeloid Leukemia ◽  
Cell Lymphoma ◽  
Mrna Level ◽  
B Cell Lymphoma ◽  
Hematologic Malignancies ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Acute Myeloid

AbstractIn this study, we performed correlation analysis of polycomb gene EED and hematologic malignancies using the omics and clinical data of acute myeloid leukemia (LAML) and diffuse large B-Cell lymphoma (DLBC) from TCGA database. We found that: (1) High EED mRNA level was associated with poor prognosis and high CALGB cytogenetics risk of LAML patients. (2) EED mRNA level in DLBC cancer cells was higher than control cells. (3) EED gene expression could be regulated by both copy number alterations and DNA methylation. (4) Additionally, there were different EED co-expression genes nets in the two kinds of hematologic malignancies. In all, we confirmed that there are potential clinical significance of EED gene in pathogenesis and prognosis of hematologic malignancies.

scholarly journals A case of primary gastric diffuse large B-cell lymphoma occurring in chronic myeloid leukemia

2019 ◽  
Vol Volume 12 ◽  
pp. 5917-5923 ◽  
Author(s):  
Zhimei Cai ◽  
Shuo Liu ◽  
Jie Zi ◽  
Jinlong Ma ◽  
Zheng Ge
Keyword(s):  
Chronic Myeloid Leukemia ◽  
B Cell ◽  
Myeloid Leukemia ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy

2019 ◽  
Vol 10 ◽  
pp. 204062071988282 ◽  
Author(s):  
Guillaume Richard-Carpentier ◽  
Courtney D. DiNardo
Keyword(s):  
Clinical Trials ◽  
Acute Myeloid Leukemia ◽  
Adverse Events ◽  
B Cell ◽  
Drug Administration ◽  
Myeloid Leukemia ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Intensive Chemotherapy ◽  
Acute Myeloid

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently, therapeutic options for these patients included low-dose cytarabine (LDAC) or the hypomethylating agents (HMA) azacitidine and decitabine, which have historically provided only short-lived and modest benefits. The oral B-cell lymphoma 2 inhibitor, venetoclax, Venetoclax, an oral B-cell lymphoma 2 (BCL2) inhibitor, is now approved by the USA Food and Drug Administration (FDA) in combination with LDAC or HMA in older AML patients ineligible for intensive chemotherapy. Is now approved by the US Food and Drug Administration for this indication. In the pivotal clinical trials evaluating venetoclax either in combination with LDAC or with HMA, the rates of complete remission (CR) plus CR with incomplete hematological recovery were 54% and 67%, respectively and the median overall survival (OS) was 10.4 months and 17.5 months, respectively, comparing favorably with outcomes in clinical trials evaluating single-agent LDAC or HMA. The most common adverse events with venetoclax combinations are gastrointestinal symptoms, which are primarily low grade and easily manageable, and myelosuppression, which may require delays between cycles, granulocyte colony-stimulating factor (G-CSF) administration, or decreased duration of venetoclax administration per cycle. A bone marrow assessment after the first cycle of treatment is critical to determine dosing and timing of subsequent cycles, as most patients will achieve their best response after one cycle. Appropriate prophylactic measures can reduce the risk of venetoclax-induced tumor lysis syndrome. In this review, we present clinical data from the pivotal trials evaluating venetoclax-based combinations in older patients ineligible for intensive chemotherapy, and provide practical recommendations for the prevention and management of adverse events associated with venetoclax.

Sign in / Sign up

Export Citation Format

Share Document